Results 1 to 10 of about 387,985 (305)
Emerging Therapies for Recurrent Pericarditis: Interleukin‐1 inhibitors [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Recurrent pericarditis (RP) is a complex inflammatory disorder associated with adverse outcomes and poor quality of life. After the first episode of acute pericarditis, a non‐negligible group of patients will fail to achieve complete remission despite ...
Saberio Lo Presti +5 more
doaj +5 more sources
Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review [PDF]
Frontiers in Pharmacology, 2022 Sepsis is a syndrome with high mortality, which seriously threatens human health. During the pandemic of coronavirus disease 2019 (COVID-19), some severe and critically ill COVID-19 patients with multiple organ dysfunction developed characteristics ...
Ying Wang +6 more
doaj +2 more sources
Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review [PDF]
Frontiers in Immunology, 2022 Newly emerging variants of coronavirus 2 (SARS-CoV-2) raise concerns about the spread of the disease, and with the rising case numbers, the Coronavirus disease 2019 (COVID-19) remains a challenging medical emergency towards the end of the year 2021 ...
Pamir Atagündüz +2 more
doaj +2 more sources
Interleukin-1 inhibitors for acute gout. [PDF]
Cochrane Database Syst Rev, 2014 Acute gout flares cause significant pain and disability and it is important to provide quick and effective pain relief. Traditional options for managing acute flares include colchicine, non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids.To assess the benefits and harms of interleukin-1 inhibitors (anakinra, canakinumab, rilonacept) in ...
Sivera F +4 more
europepmc +3 more sources
Is It Time to Revisit the Role of Interleukin-1 Inhibitors in Osteoarthritis? [PDF]
Diabetes, Metabolic Syndrome and ObesityMartin Brom,1 Franziska Saxer,1,2 Linda Mindeholm,1 Matthias Schieker,1 Philip G Conaghan3 1Translational Medicine, Novartis Biomedical Research, Basel, Switzerland; 2Medical Faculty, University of Basel, Basel, Switzerland; 3Leeds Institute of Rheumatic
Brom M +4 more
doaj +2 more sources
Interleukin 1 inhibitors in monogenic autoinflammatory diseases – one size does not fit all [PDF]
Rheumatology, 2021 Ewa Więsik-Szewczyk
doaj +2 more sources
International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. [PDF]
Rheumatology (Oxford), 2017 To provide outcome data concerning pregnancies exposed to the Interleukin-1 (IL-1) inhibitors prior to conception in both men and women, during pregnancy and breast feeding.Retrospective data were collected from members of the International Society for Systemic Autoinflammatory diseases and collated in a single centre.
Youngstein T +18 more
europepmc +5 more sources
Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics [PDF]
Journal of Inflammation ResearchAlice Tang,1 Grace Rachko,2 Flavia Manzo Margiotta,1,3,4 Jasmine Levine,1 Ester Del Duca,1,5 Benjamin Ungar1 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Rutgers New Jersey Medical School, Newark, NJ, USA ...
Tang A +5 more
doaj +2 more sources
Современная ревматология, 2021 Autoinflammatory diseases (AIDs) are a heterogeneous group of rare genetically determined conditions, the main manifestations of which are episodes of fever in combination with other signs of systemic inflammation: skin rashes, musculoskeletal and ...
S. O. Salugina, E. S. Fedorov
doaj +1 more source
Dermatology and Therapy, 2023 Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation of TNF inhibitors.
Megumi Kishimoto +6 more
doaj +1 more source